Conflict of interest
The efficacy of single dose ivermectin in the treatment of hookworm related cutaneous larva migrans varies depending on the clinical presentation
Article first published online: 1 FEB 2013
© 2013 The Authors Journal of the European Academy of Dermatology and Venereology © 2013 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 28, Issue 5, pages 655–657, May 2014
How to Cite
Vanhaecke, C., Perignon, A., Monsel, G., Regnier, S., Bricaire, F. and Caumes, E. (2014), The efficacy of single dose ivermectin in the treatment of hookworm related cutaneous larva migrans varies depending on the clinical presentation. Journal of the European Academy of Dermatology and Venereology, 28: 655–657. doi: 10.1111/jdv.12097
- Issue published online: 22 APR 2014
- Article first published online: 1 FEB 2013
- Manuscript Accepted: 17 DEC 2012
- Manuscript Received: 25 SEP 2012
Treatment of hookworm-related cutaneous larva migrans (HrCLM) with a single dose of oral ivermectin has not been adequately evaluated to date. Response rates reported in three large studies varied from 77% to more than 95%.
We evaluated the efficacy of ivermectin in the treatment of HrCLM.
We retrospectively studied all returning travellers with HrCLM who consulted in our institution. Patients were then treated with a single, 200 μg/kg dose of ivermectin, orally.
Sixty-two travellers (35 female, 27 male, mean age 35.6 years) with HrCLM and creeping dermatitis were included. Six patients (10%) also had associated hookworm folliculitis. Fifty-nine patients (95%) completely responded with one ivermectin dose. The response rate was 98% in the 56 patients presenting with only creeping dermatitis and 66% in the six patients presenting with additional hookworm folliculitis (P = 0.02).
The efficacy of a single dose of oral ivermectin is higher in patients with only creeping dermatitis than in those with associated hookworm folliculitis.